Logo
x

Search

Subscribe Now

Merck

Merck Reports Topline Data from P-III Studies of Doravirine/Islatravir (DOR/ISL) Regimen to Treat Virologically Suppressed HIV-1 Infection

Merck Reports Topline Data from P-III Studies of Doravirine/Islatravir (DOR/ISL) Regimen to Treat Virologically Suppressed HIV-1 I...

  • December 23, 2024
Merck Join Forces with Hansoh Pharma to Develop HS-10535

Merck Join Forces with Hansoh Pharma to Develop HS-10535

  • December 20, 2024
Merck Discontinues Clinical Development Programs Evaluating Vibostolimab and Favezelimab for Various Indications

Merck Discontinues Clinical Development Programs Evaluating Vibostolimab and Favezelimab for Various Indications

  • December 19, 2024
Merck Reports the US FDA’s BLA Acceptance of Clesrovimab to Protect Infants from RSV Disease

Merck Reports the US FDA’s BLA Acceptance of Clesrovimab to Protect Infants from RSV Disease

  • December 18, 2024
China's NMPA Approves Merck’s Keytruda Plus Chemotherapy as Neoadjuvant Treatment of NSCLC

China's NMPA Approves Merck’s Keytruda Plus Chemotherapy as Neoadjuvant Treatment of NSCLC

  • December 17, 2024
Merck Reports the CHMP’s Positive Opinion of Welireg (Belzutifan) for Von Hippel-Lindau (VHL) Disease-Associated Tumors and Previously Treated Renal Cell Carcinoma

Merck Reports the CHMP’s Positive Opinion of Welireg (Belzutifan) for Von Hippel-Lindau (VHL) Disease-Associated Tumors and Previo...

  • December 16, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.